Aptevo Therapeutics (NASDAQ:APVO) Issues Earnings Results

Aptevo Therapeutics (NASDAQ:APVO) posted its quarterly earnings results on Thursday. The biotechnology company reported $118.23 EPS for the quarter, beating the consensus estimate of ($8.10) by $126.33, FiscalAI reports.

Aptevo Therapeutics Price Performance

Aptevo Therapeutics stock traded up $0.08 during trading hours on Thursday, reaching $4.51. The stock had a trading volume of 46,631 shares, compared to its average volume of 177,411. The company has a market cap of $4.51 million, a price-to-earnings ratio of 0.00 and a beta of 1.44. The business’s 50 day moving average price is $6.72 and its 200-day moving average price is $17.25. Aptevo Therapeutics has a 52 week low of $3.95 and a 52 week high of $1,299.60.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on APVO. Wall Street Zen downgraded shares of Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings restated a “sell (e)” rating on shares of Aptevo Therapeutics in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Aptevo Therapeutics currently has an average rating of “Hold”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC bought a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned about 1.16% of Aptevo Therapeutics at the end of the most recent reporting period. Institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.